Confidential hepatitis B and hepatitis C screening can help identify current infection, previous exposure and—particularly for hepatitis B—whether vaccination protection may be needed. These viruses affect the liver, may remain silent for years and require different tests and prevention pathways. STDtest.clinic can coordinate clinically indicated blood testing and medical interpretation in Dubai, with home or hotel sample collection only where the service, specimen transport and licensed scope are confirmed.
Hepatitis B and Hepatitis C: Why Sexual-Health Testing Matters
Hepatitis B virus (HBV) can be transmitted through sexual contact, blood exposure and from a pregnant person to their baby. Hepatitis C virus (HCV) is predominantly blood-borne; sexual transmission occurs but is generally less efficient, with risk increasing in circumstances involving blood exposure, mucosal injury, certain sexual networks or coexisting HIV. Neither infection can be diagnosed from symptoms alone.
A person may have normal energy levels and no jaundice while carrying an infection that needs evaluation. Conversely, abnormal liver enzymes do not establish which hepatitis virus is responsible. A properly chosen blood panel, interpreted with exposure timing and previous vaccination or treatment, provides a much more reliable answer.
Who Should Consider Hepatitis B and C Testing?
Testing is relevant after a partner reports HBV or HCV, after possible blood-to-blood exposure, following a needlestick or sharing of injecting equipment, or when a clinician identifies other risk factors. Hepatitis B assessment is also useful when vaccination records are missing or before certain immunosuppressive treatments. Screening can be part of a broader sexual-health consultation following condom failure, a new partner, or HIV exposure, but not every exposure has the same likelihood of HBV and HCV transmission.
Adults may benefit from one-time screening even without a known recent exposure under widely used public-health recommendations. Pregnancy requires specific antenatal testing pathways, including HBsAg screening and risk-based or recommended HCV screening under the applicable local protocol. A clinician should account for prior infection, liver disease, immunosuppression, dialysis, transfusion or procedural history and previous antiviral treatment.
Hepatitis B Blood Tests: HBsAg, Anti-HBs and Anti-HBc
The hepatitis B triple panel—HBsAg, anti-HBs and total anti-HBc—helps distinguish infection, immunity and susceptibility. HBsAg (hepatitis B surface antigen) indicates a current HBV infection when confirmed and interpreted appropriately; further testing is needed to determine whether it is acute or chronic. Anti-HBs (surface antibody) may indicate vaccine response or recovery from natural infection. Total anti-HBc (core antibody) indicates exposure to HBV at some point and is not produced by vaccination alone.
HBsAg negative, anti-HBc negative and anti-HBs positive is a typical pattern after vaccination. HBsAg negative, anti-HBc positive and anti-HBs positive generally suggests resolved natural infection. All three negative usually indicates susceptibility, subject to clinical context. HBsAg positive warrants medical assessment for current infection. These are common patterns, not a substitute for evaluating unusual or discordant combinations.
An isolated positive anti-HBc result can reflect past infection with waning anti-HBs, a false positive, occult HBV infection or a window-phase infection. The next step depends on risk, immune status and whether HBV DNA or repeat serology is indicated. Anti-HBs at or above 10 mIU/mL is a recognized correlate of protection after a documented complete vaccination series in people for whom post-vaccination testing is recommended; a lower titre years later does not automatically mean an immunocompetent previously vaccinated person has lost protection.
Additional Hepatitis B Markers: IgM Anti-HBc, HBV DNA, HBeAg and Liver Tests
If recent acute infection is suspected, IgM anti-HBc can assist diagnosis, though interpretation is nuanced because it may also occur during flares of chronic hepatitis B. HBV DNA quantitative PCR measures viral DNA in blood and helps assess replication, treatment eligibility and monitoring. HBeAg and anti-HBe provide additional context for viral activity, but do not replace HBV DNA. ALT, AST, bilirubin, albumin, platelet count and other tests evaluate liver injury or function rather than diagnosing HBV on their own.
A person with persistent HBsAg positivity for at least six months is generally classified as having chronic HBV infection. Clinical assessment also considers liver fibrosis, other infections, pregnancy, medications, alcohol intake and family history of liver cancer. Patients should not assume that a low viral load or normal ALT means no follow-up is needed.
Hepatitis C Testing: Antibody Screening Followed by HCV RNA
Anti-HCV antibody screening identifies evidence of past exposure to hepatitis C but does not by itself distinguish current infection from previously cleared or successfully treated infection. When antibody is reactive, HCV RNA NAT/PCR is required to determine whether virus is currently detectable. Ideally, the laboratory uses a reflex pathway so an antibody-positive sample is automatically tested for HCV RNA without a second appointment when technically possible.
Anti-HCV reactive and HCV RNA detected indicates current HCV infection and requires clinical linkage to treatment. Anti-HCV reactive and HCV RNA not detected usually means no current infection, although recent exposure or specimen-related concerns may require follow-up. Anti-HCV negative does not reliably exclude very recent infection or infection in certain immunocompromised patients; HCV RNA may be the appropriate initial test in those circumstances.
HCV antibody often remains positive after cure, so repeating an antibody test is not a way to determine whether treatment worked or whether a previously treated person has become reinfected. HCV RNA is used for those questions.
Hepatitis B Versus Hepatitis C: Key Differences
Hepatitis B: a vaccine is available; sexual transmission is well established; a three-marker serological panel clarifies status; chronic infection may require long-term monitoring and antiviral suppression. Hepatitis C: no vaccine is currently available; transmission is primarily through blood, with sexual risk varying by circumstances; antibody screening plus RNA determines current infection; modern direct-acting antivirals can cure most patients.
Testing Windows After a Recent Exposure
A negative test immediately after exposure cannot exclude a newly acquired hepatitis infection. The detection timeline varies by virus, assay and individual. HBsAg may become detectable several weeks after HBV infection; HBV DNA can appear earlier. Anti-HCV antibody commonly becomes detectable roughly 8–11 weeks after infection, while HCV RNA may be detectable within about 1–2 weeks. These are approximate biological ranges, not guarantees for an individual result.
For possible HCV exposure, clinicians may arrange baseline anti-HCV with reflex RNA, early HCV RNA testing around 3–6 weeks when indicated, and later antibody testing around 4–6 months depending on the exposure and protocol. For HBV, baseline status, vaccination history, source-patient results and any post-exposure prophylaxis determine follow-up, sometimes including repeat HBsAg and anti-HBc testing months later. Do not select repeat dates without considering the exact exposure and local occupational or sexual-exposure guidance.
Recent Hepatitis B Exposure: Vaccination and HBIG Can Be Time-Sensitive
If a person may have been exposed to hepatitis B and is not known to be protected, urgent assessment is appropriate. Post-exposure management may involve hepatitis B vaccination, hepatitis B immune globulin (HBIG), both, or neither, based on the source status, type of exposure and documented immunity. HBIG provides temporary passive antibodies; vaccination aims to establish longer-term immunity.
When HBIG is indicated, it should be given as soon as possible—preferably within 24 hours. Its effectiveness after more than 7 days for percutaneous exposure or 14 days for sexual exposure is uncertain in commonly used CDC guidance. These are not waiting periods: assessment should happen immediately. Patients should not delay urgent preventive care while waiting for routine package results.
A clinician should distinguish sexual exposure, needlestick exposure, household contact and occupational injury because the source testing and follow-up algorithms differ. The availability of HBIG, vaccination and their administration must be confirmed with an appropriately licensed facility; do not promise on-demand home HBIG.
Hepatitis B Vaccination, Immunity and Booster Decisions
Hepatitis B vaccination is an effective preventive measure. Depending on the product and local authorization, primary schedules may use two or three doses, with some special populations requiring different regimens. International examples include Engerix-B and Recombivax HB (often three-dose schedules) and Heplisav-B (two-dose adult schedule in jurisdictions where approved). Brand availability, age indications and schedules must be checked against current UAE registration and the actual clinic stock.
A person with a documented completed vaccine series does not automatically need a booster because their current anti-HBs result is low. Routine post-vaccination antibody testing is not required for everyone, but is recommended for certain groups, such as healthcare personnel, some immunocompromised people and sexual partners of people with HBsAg-positive infection. For people with inadequate response, the clinician may recommend additional doses or repeat vaccination according to the relevant protocol.
Symptoms of Acute and Chronic Hepatitis
Many people with hepatitis B or C have no symptoms. When acute hepatitis produces symptoms, they may include unusual fatigue, reduced appetite, nausea, abdominal discomfort, dark urine, pale stools, fever, joint aches and yellowing of the skin or eyes. These symptoms are not specific to viral hepatitis and require assessment rather than self-diagnosis.
Chronic infection may remain silent while liver inflammation and fibrosis progress. Severe jaundice, confusion, unusual bleeding, significant abdominal swelling, persistent vomiting or marked deterioration require urgent facility-based evaluation. A home blood draw is not a substitute for emergency care.
Hepatitis B Treatment and Long-Term Monitoring
Not everyone with hepatitis B requires immediate antiviral medication. Decisions depend on HBV DNA, ALT, fibrosis or cirrhosis, pregnancy, immune status, coinfections and other risk factors. For patients who need treatment, commonly used first-line oral antivirals include tenofovir disoproxil fumarate (TDF) 300 mg once daily, tenofovir alafenamide (TAF) 25 mg once daily in appropriate patients, and entecavir 0.5 mg once daily in certain treatment-naïve adults. Doses, renal adjustment, eligibility and formulations vary; these are educational examples, not prescriptions.
TAF and TDF differ in kidney and bone considerations, and entecavir requires attention to HIV coinfection and resistance history. Antivirals usually suppress HBV rather than eradicate it; stopping them without medical supervision can provoke severe hepatitis flares. Patients may need long-term monitoring for liver disease and, when indicated, hepatocellular carcinoma surveillance even with effective viral suppression.
Hepatitis C Treatment: Direct-Acting Antivirals
Most people with current hepatitis C can be cured with an appropriate course of direct-acting antiviral (DAA) tablets. Widely used pangenotypic examples include sofosbuvir/velpatasvir 400/100 mg once daily for 12 weeks and glecaprevir/pibrentasvir 300/120 mg once daily with food for 8 weeks in eligible treatment-naïve adults. The latter total daily dose is typically supplied as three 100/40 mg tablets. These examples are not interchangeable for every patient.
Before treatment, clinicians assess cirrhosis, prior HCV therapy, kidney function, drug interactions, hepatitis B status, pregnancy and other relevant factors. Protease-inhibitor-containing regimens such as glecaprevir/pibrentasvir are not appropriate in decompensated cirrhosis. HBV reactivation is an important risk to assess before DAA therapy. Sustained virological response—undetectable HCV RNA at least 12 weeks after completing treatment—is the usual marker of cure. Cure does not prevent future reinfection.
Brand names, UAE authorization, dispensing pathways and actual medicine availability must be verified rather than advertised as guaranteed stock. Patients with advanced liver disease or complex coinfections require specialist-led treatment.
Hepatitis Screening Alongside HIV, Syphilis and Other STI Tests
A sexual-health assessment may combine hepatitis tests with HIV antigen/antibody testing, syphilis serology and site-specific chlamydia or gonorrhea NAAT when clinically appropriate. The decision should be based on exposure and previous results, not on the largest possible list of markers. Hepatitis A assessment or vaccination may also be relevant for some people, but it is a distinct infection with a different testing pathway.
People starting HIV PEP need timely baseline evaluation that may include hepatitis B and C markers, kidney and liver tests and HIV testing. PEP should not be delayed when urgently indicated while waiting for hepatitis results. A substantial possible HIV exposure within 72 hours requires urgent PEP assessment; ideally PEP starts as soon as possible. Hepatitis B prophylaxis may need separate action in parallel.
People using or considering HIV PrEP also need hepatitis B assessment because some oral PrEP medicines are active against HBV and stopping them can trigger a hepatitis flare in a person with chronic HBV. HIV PrEP does not prevent hepatitis C. Any decision to start, stop or change these medicines should be clinician-led.
Pregnancy, Newborn Protection and Family Considerations
Hepatitis B screening during pregnancy is essential for preventing mother-to-child transmission. If the pregnant patient is HBsAg-positive, additional testing and specialist management determine whether antiviral treatment during pregnancy is indicated. Newborns exposed to HBV require time-sensitive vaccine and HBIG management according to the birth protocol, followed by appropriate post-vaccination testing. This care must be coordinated with obstetric and neonatal services.
HCV screening and management in pregnancy follow separate guidance. Direct-acting antiviral treatment during pregnancy is not routine in many guidelines because evidence is limited; specialist advice is needed. Breastfeeding advice depends on the infection and circumstances, including whether nipples are cracked or bleeding. Families should avoid sharing razors, toothbrushes or other items that may contain blood, while understanding that ordinary social contact does not spread hepatitis B or C.
Home and Hotel Hepatitis Blood Testing in Dubai
Selected hepatitis B and C blood samples may be collected at a home or hotel when the collection pathway is authorized and validated. The process can include a confidential clinical discussion, identity and consent checks, venous blood collection, secure labeling, appropriate specimen transport and laboratory processing. The healthcare professional should confirm whether the laboratory can perform reflex HCV RNA, quantitative HBV DNA or additional serology from the collected sample.
Assessment → appropriate panel → blood collection → laboratory testing → clinician interpretation → vaccination, treatment or referral plan. Results should be explained in terms of current infection, previous exposure, immunity, susceptibility and any need for repeat testing. Not all laboratory tests are available on every mobile visit, and laboratory analysis should not be marketed as an instant bedside result unless that exact validated service exists.
Patients in Arjan, Dubai Marina, JBR, JLT, Palm Jumeirah, Downtown Dubai, Business Bay, DIFC, Jumeirah, Al Barsha, Dubai Hills Estate, Emirates Hills, Arabian Ranches and Dubai Creek Harbour may enquire about collection availability. Requests from Abu Dhabi and Sharjah can be checked individually; naming these areas does not guarantee licensed mobile coverage.
Confidentiality, Reporting and What Happens After a Positive Result
Medical confidentiality is important, but hepatitis testing is not necessarily anonymous. Identity verification, clinical documentation, laboratory reporting and public-health notification must follow applicable UAE law and facility procedures. The team should explain who receives results, how records are protected and whether further specialist referral is needed.
A positive HBsAg or detectable HCV RNA result is a reason for timely medical follow-up, not panic. The clinician may order viral load, liver tests, fibrosis assessment, coinfection testing or imaging as appropriate, and discuss vaccination of susceptible contacts. A positive anti-HCV antibody alone is not a diagnosis of current hepatitis C. Patients should not begin or discontinue antiviral medication based only on a screening report.
Book Hepatitis B & C Sexual Health Testing in Dubai
When booking, share the approximate exposure date, whether the exposure was sexual or blood-related, any partner results, vaccination records, previous hepatitis diagnoses, current medications, pregnancy and recent HIV PEP or PrEP use. These details help identify the correct markers and whether urgent prophylaxis is required.
Medical Information Notice
This information is educational and does not replace a clinician’s assessment. Hepatitis testing, vaccine decisions, HBIG, antivirals and follow-up must follow current evidence, applicable UAE regulations and individual clinical circumstances. Seek urgent care after a significant recent exposure or if severe symptoms develop.